📰 Mark Oki News
Mark Oki News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Oki. Real-time updates on events, politics, business and more.
May 16, 2024
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023TTM March 2024 operating income of $7.3 million for the Rx BusinessTTM March 2024 companywide adjusted EBITDA of positive $15.4 millionTTM March 2024 adjusted EBITDA of positive $17.1 mi...
February 16, 2024
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript February 14, 2024 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.25. Aytu BioPharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to the […]
February 14, 2024
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted EBITDA of $5.5 millionQ2 2024 ADHD Portfolio net revenue up 49% compared to Q2 2023$19.5 million cash balance at Decem...
February 8, 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December...
February 7, 2024
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational ...
January 23, 2024
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners ...
January 23, 2024
DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lyt...
November 30, 2023
30.11.2023 - Webcasted presentation to take place at 1:10pm ETDENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or Aytu) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that ...
November 15, 2023
Robert Blum: Good afternoon, everyone, and thank you for joining us for Aytu BioPharmas Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023.
November 8, 2023
08.11.2023 - Ranked 118th Fastest Growing Company in North AmericaRanked 23rd Fastest Growing Life Sciences CompanyDENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or Aytu) (NASDAQ:AYTU), a pharmaceutical company focused on ...